CCCC Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . C4 Therapeutics
CCCC Stock  USD 1.82  0.11  6.43%   
C4 Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing C4 Therapeutics' valuation are provided below:
Gross Profit
-81.7 M
Market Capitalization
183.2 M
Enterprise Value Revenue
2.1543
Revenue
30.1 M
Earnings Share
(1.57)
We have found one hundred twenty available fundamental measures for C4 Therapeutics, which can be analyzed and compared to other ratios and to its peers in the sector. Investors should ensure to validate all of C4 Therapeutics' latest performance against the performance from 2010 to 2026 to make sure the company is sustainable this quarter and beyond. As of February 6, 2026, Market Cap is expected to decline to about 306.4 M. In addition to that, Enterprise Value is expected to decline to about 245.7 M

C4 Therapeutics Total Revenue

32.55 Million

Check C4 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among C4 Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 230.2 K, Net Interest Income of 17.4 M or Interest Income of 17.4 M, as well as many indicators such as Price To Sales Ratio of 7.67, Dividend Yield of 0.0 or PTB Ratio of 1.09. CCCC financial statements analysis is a perfect complement when working with C4 Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with CCCC Stock
Check out the analysis of C4 Therapeutics Correlation against competitors.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

C4 Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets365.9 M402 M251.1 M
Slightly volatile
Short and Long Term Debt Total50 M75.6 M32.9 M
Slightly volatile
Other Current Liabilities14.5 M22.3 M9 M
Slightly volatile
Total Current Liabilities44.8 M52 M33.7 M
Slightly volatile
Other Liabilities14.4 M15.2 M54.6 M
Slightly volatile
Property Plant And Equipment Net47.6 M72.9 M34.5 M
Slightly volatile
Current Deferred Revenue17.1 M16.8 M19.8 M
Very volatile
Accounts Payable2.4 M1.2 M2 M
Slightly volatile
Cash68.2 M49.9 M59.1 M
Slightly volatile
Non Current Assets Total91.9 M105.6 M56.8 M
Slightly volatile
Non Currrent Assets Other4.5 M7 M3.6 M
Slightly volatile
Other Assets3.6 M5.5 M3.3 M
Slightly volatile
Cash And Short Term Investments248.7 M281.6 M141.4 M
Slightly volatile
Net Receivables2.7 M2.8 M47.9 M
Slightly volatile
Common Stock Shares Outstanding53.8 M79.8 M47.8 M
Slightly volatile
Liabilities And Stockholders Equity365.9 M402 M251.1 M
Slightly volatile
Non Current Liabilities Total93 M79.6 M153.2 M
Slightly volatile
Capital Lease Obligations44.9 M75.6 M30.7 M
Slightly volatile
Other Current Assets16.4 M11.2 M8.1 M
Slightly volatile
Total Liabilities125.5 M120.3 M185.5 M
Slightly volatile
Property Plant And Equipment Gross52.6 M83.5 M37.3 M
Slightly volatile
Total Current Assets274 M296.4 M194.2 M
Slightly volatile
Net Working Capital229.2 M244.5 M160.5 M
Slightly volatile
Short Term Debt3.5 M6.6 M2.2 M
Slightly volatile
Common Stock4.6 K8.1 K2.9 K
Slightly volatile
Property Plant Equipment10.6 M6.7 M15.4 M
Slightly volatile
Long Term Debt8 M8.3 M9.7 M
Slightly volatile
Common Stock Total Equity5.1 K5.8 K4.4 K
Slightly volatile
Short Term Investments157.8 M170.5 M189.1 M
Pretty Stable
Long Term Debt Total8 M8.3 M9.7 M
Slightly volatile
Capital Surpluse664.4 M792.6 M546.7 M
Slightly volatile
Deferred Long Term Liabilities31.2 M21.9 M43.6 M
Slightly volatile
Non Current Liabilities Other106.1 M101 M37.2 M
Slightly volatile
Short and Long Term Debt1.8 M2.1 M2.2 M
Slightly volatile

C4 Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income17.4 M16.6 M4.1 M
Slightly volatile
Depreciation And Amortization3.1 M2.1 M3.1 M
Pretty Stable
Selling General Administrative30.1 M48.4 M19.2 M
Slightly volatile
Total Revenue32.6 M40.9 M25.6 M
Slightly volatile
Other Operating Expenses124.1 M178.5 M81.1 M
Slightly volatile
Research Development93.6 M127.2 M61.5 M
Slightly volatile
Cost Of Revenue6.7 M7.1 M24.9 M
Slightly volatile
Total Operating Expenses110.6 M178.5 M75.2 M
Slightly volatile
Reconciled Depreciation1.8 M2.1 M1.5 M
Slightly volatile
Selling And Marketing Expenses6.2 M7 M7.6 M
Slightly volatile

C4 Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation17.9 M34.1 M10 M
Slightly volatile
Begin Period Cash Flow90.5 M149.5 M56 M
Slightly volatile
Depreciation1.8 M2.1 M1.5 M
Slightly volatile
Other Non Cash Items1.1 M1.2 M2.4 M
Very volatile
Capital Expenditures153.9 K162 K2.1 M
Slightly volatile
Total Cash From Financing Activities70.2 M40.8 M43.6 M
Slightly volatile
End Period Cash Flow70.6 M53 M61.9 M
Slightly volatile
Change To Netincome36.2 M34.5 M11.8 M
Slightly volatile
Dividends Paid9.6 M10.8 M11.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.678.0720.4318
Pretty Stable
Days Sales Outstanding34.7636.59892
Slightly volatile
Stock Based Compensation To Revenue0.430.750.3066
Slightly volatile
Capex To Depreciation0.110.0991.5071
Slightly volatile
EV To Sales7.988.419.3052
Pretty Stable
Payables Turnover5.856.1516.7056
Slightly volatile
Sales General And Administrative To Revenue0.751.070.6665
Slightly volatile
Research And Ddevelopement To Revenue2.372.82.2181
Slightly volatile
Capex To Revenue0.00550.00580.0962
Slightly volatile
Cash Per Share3.913.183.5845
Slightly volatile
Days Payables Outstanding64.4661.3934.3641
Slightly volatile
Current Ratio4.755.145.455
Pretty Stable
Receivables Turnover6.2410.324.2915
Slightly volatile
Capex Per Share0.00280.0030.1098
Slightly volatile
Revenue Per Share0.80.591.0003
Slightly volatile
Interest Debt Per Share0.810.850.9745
Very volatile
Debt To Assets0.10.170.1175
Slightly volatile
Operating Cycle34.7636.59892
Slightly volatile
Days Of Payables Outstanding64.4661.3934.3641
Slightly volatile
Ebt Per Ebit1.071.010.9746
Slightly volatile
Long Term Debt To Capitalization0.03390.03540.0335
Slightly volatile
Quick Ratio4.915.145.5449
Pretty Stable
Net Income Per E B T1.111.151.0319
Slightly volatile
Cash Ratio2.311.411.7967
Pretty Stable
Cash Conversion Cycle34.7636.59879
Slightly volatile
Days Of Sales Outstanding34.7636.59892
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.1045
Slightly volatile
Fixed Asset Turnover1.050.650.938
Pretty Stable
Debt Ratio0.10.170.1175
Slightly volatile
Price Sales Ratio7.678.0720.4318
Pretty Stable
Asset Turnover0.110.120.1178
Slightly volatile

C4 Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap306.4 M322.5 M522.1 M
Pretty Stable
Enterprise Value245.7 M258.6 M484.2 M
Very volatile

CCCC Fundamental Market Drivers

CCCC Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About C4 Therapeutics Financial Statements

C4 Therapeutics stakeholders use historical fundamental indicators, such as C4 Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although C4 Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in C4 Therapeutics' assets and liabilities are reflected in the revenues and expenses on C4 Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in C4 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue16.8 M17.1 M
Total Revenue40.9 M32.6 M
Cost Of Revenue7.1 M6.7 M
Stock Based Compensation To Revenue 0.75  0.43 
Sales General And Administrative To Revenue 1.07  0.75 
Research And Ddevelopement To Revenue 2.80  2.37 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.59  0.80 
Ebit Per Revenue(3.87)(4.06)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:
How To Invest In CCCC
Details
Is CCCC Stock a good investment?
Details
What is C4 Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of C4 Therapeutics Correlation against competitors.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Will Biotechnology sector continue expanding? Could CCCC diversify its offerings? Factors like these will boost the valuation of C4 Therapeutics. Projected growth potential of CCCC fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every C4 Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.57)
Revenue Per Share
0.423
Quarterly Revenue Growth
(0.27)
Return On Assets
(0.23)
Return On Equity
(0.60)
Understanding C4 Therapeutics requires distinguishing between market price and book value, where the latter reflects CCCC's accounting equity. The concept of intrinsic value - what C4 Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push C4 Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between C4 Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding C4 Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, C4 Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY